Study of PML risk in MS patients taking Zeposia
Treatments studied
Part of Brain & nervous system, Immune system & allergy, Infections clinical trials.
This study looks at people with multiple sclerosis who have taken Zeposia (ozanimod) and later developed a rare brain infection called PML. The goal is to understand how often this happens and to confirm cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple sclerosis and have taken at least one dose of Zeposia (ozanimod).
- You had a positive test for JC virus in your spinal fluid, or were diagnosed with PML (a rare brain infection).
- Your PML case was reported to the drug company between June 2026 and July 2041.
- You reported this as part of a spontaneous report, an observational study, or a patient support program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if pembrolizumab, an immunotherapy drug, can help fight a rare brain virus called PML in people whose immune systems are weakened but not due to HIV. The goal is to see if it improves recovery.
This study follows people with suspected or confirmed progressive multifocal leukoencephalopathy (PML), people at higher risk, and healthy volunteers. It uses visits, brain imaging (MRI), and stored biological samples to better understand how PML progresses and who is at risk.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This Phase 1 study tests a small drug (called an anti–CD8+ T cell minibody) to see how much reaches the brain. It may help researchers understand how to deliver similar treatments for multiple sclerosis, progressive multifocal leukoencephalopathy (PML), or other brain inflammation when the brain’s protective barrier is “open.”
This study follows patients with chronic viral infections affecting the brain and spinal cord. Researchers will collect spinal fluid samples and track your health over one year to better understand these infections and improve care.
This trial looks at the safety of ozanimod taken during pregnancy for parents with multiple sclerosis and for their babies after birth. It may help doctors understand the risks and benefits of this medicine during early pregnancy.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.